Cimlanod

Cimlanod (BMS-986231) is a second-generation Nitroxyl (HNO) donor for heart failure. Cimlanod (BMS-986231) delivers HNO via pH-dependent chemical breakdown when exposed to the neutral pH environment of the bloodstream. Cimlanod (BMS-986231) possesses positive lusitropic and inotropic as well as vasodilatory effects. Cimlanod is the prodrug of CXL-1020 (HY-147384) [1][2].

Product Specifications

CAS Number

[1620330-72-4]

Product Name Alternative

BMS-986231; CXL-1427

UNSPSC

12352005

Target

Drug Intermediate

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cimlanod.html

Purity

99.82

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(O1)C)(NO)=O

Molecular Formula

C5H7NO4S

Molecular Weight

177.18

References & Citations

[1]Cowart D, et al. A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers. J Clin Pharmacol. 2019 May;59 (5) :717-730.|[2]Felker GM, et al. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. Eur J Heart Fail. 2019 Aug;21 (8) :1022-1031.|[3]Hartman JC, et al., Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure. JACC Basic Transl Sci. 2018 Nov 12;3 (5) :625-638.